Predictors of first pass isolation of the pulmonary veins in real world ablations: An analysis of 2671 patients from the REAL-AF registry.

atrial fibrillation atrial fibrillation ablation atrial remodeling first pass isolation high frequency low tidal volume high power short duration obesity pulmonary vein isolation

Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
28 Jan 2024
Historique:
revised: 08 01 2024
received: 26 11 2023
accepted: 12 01 2024
medline: 29 1 2024
pubmed: 29 1 2024
entrez: 29 1 2024
Statut: aheadofprint

Résumé

During atrial fibrillation ablation (AFA), achievement of first pass isolation (FPI) reflects effective lesion formation and predicts long-term freedom from arrhythmia recurrence. We aim to determine the clinical and procedural predictors of pulmonary vein FPI. We reviewed AFA procedures in a multicenter prospective registry of AFA (REAL-AF). A multivariate ordinal logistic regression, weighted by inverse proceduralist volume, was used to determine predictors of FPI. A total of 2671 patients were included with 1806 achieving FPI in both vein sides, 702 achieving FPI in one, and 163 having no FPI. Individually, age, left atrial (LA) scar, higher power usage (50 W), greater posterior contact force, ablation index >350 posteriorly, Vizigo™ sheath utilization, nonstandard ventilation, and high operator volume (>6 monthly cases) were all related to improved odds of FPI. Conversely sleep apnea, elevated body mass index (BMI), diabetes mellitus, LA enlargement, antiarrhythmic drug use, and center's higher fluoroscopy use were related to reduced odds of FPI. Multivariate analysis showed that BMI > 30 (OR 0.78 [0.64-0.96]) and LA volume (OR per mL increase = 1.00 [0.99-1.00]) predicted lower odds of achieving FPI, whereas significant left atrial scarring (>20%) was related to higher rates of FPI. Procedurally, the use of high power (50 W) (OR 1.32 [1.05-1.65]), increasing force posteriorly (OR 2.03 [1.19-3.46]), and nonstandard ventilation (OR 1.26 [1.00-1.59]) predicted higher FPI rates. At a site level, high procedural volume (OR 1.89 [1.48-2.41]) and low fluoroscopy centers (OR 0.72 [0.61-0.84]) had higher rates of FPI. FPI rates are affected by operator experience, patient comorbidities, and procedural strategies. These factors may be postulated to impact acute lesion formation.

Identifiants

pubmed: 38282445
doi: 10.1111/jce.16190
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Biosense Webster

Informations de copyright

© 2024 Wiley Periodicals LLC.

Références

Ninomiya Y, Inoue K, Tanaka N, et al. Absence of first-pass isolation is associated with poor pulmonary vein isolation durability and atrial fibrillation ablation outcomes. J Arrhythm. 2021;37:1468-1476.
Osorio J, Hunter TD, Rajendra A, Zei P, Silverstein J, Morales G. Predictors of clinical success after paroxysmal atrial fibrillation catheter ablation. J Cardiovasc Electrophysiol. 2021;32:1814-1821.
Ho G, Lin AY, Krummen DE. Linking electrical drivers with atrial cardiomyopathy for the targeted treatment of atrial fibrillation. Front Physiol. 2020;11:570740.
Varley AL, Kreidieh O, Godfrey BE, et al. A prospective multi-site registry of real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (real-AF): design and objectives. J Interv Card Electrophysiol. 2021;62:487-494.
Yamada T, Murakami Y, Okada T, et al. Incidence, location, and cause of recovery of electrical connections between the pulmonary veins and the left atrium after pulmonary vein isolation. EP Europace. 2006;8:182-188.
Kreidieh O, Varley AL, Romero J, et al. Practice patterns of operators participating in the real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (REAL-AF) registry. J Interv Card Electrophysiol. 2022;65:429-440.
Osorio J, Zei PC, Díaz JC, et al. High-frequency low-tidal-volume ventilation improves long-term outcomes in atrial fibrillation ablation: a multicenter prospective study. JACC Clin Electrophysiol. 2023; 9(8 Pt 2):1543-1554.
Osorio J, Varley A, Kreidieh O, et al. High-frequency, low-tidal-volume mechanical ventilation safely improves catheter stability and procedural efficiency during radiofrequency ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2022;15:e010722.
Kadado AJ, Gobeil K, Fakhoury F, Pervaiz A, Chalhoub F. Very low tidal volume, high-frequency ventilation in atrial fibrillation ablation: a systematic review. J Interv Card Electrophysiol. 2022;64:539-543.
Li M, Ma Y, Lin Q, et al. Comparison between high-power short-duration and conventional ablation strategy in atrial fibrillation: an updated meta-analysis. Cardiovasc Ther. 2022;2022:1-17.
Chen C, Wu J, Jin C, Liu M, Xu Y. Comparison of high-power short-duration and low-power long-duration radiofrequency ablation for treating atrial fibrillation: systematic review and meta-analysis. Clin Cardiol. 2020;43:1631-1640.
Leung LWM, Akhtar Z, Sheppard MN, Louis-Auguste J, Hayat J, Gallagher MM. Preventing esophageal complications from atrial fibrillation ablation: a review. Heart Rhythm O2. 2021;2:651-664.
Zhang X, Kuang X, Gao X, et al. RESCUE-AF in patients undergoing atrial fibrillation ablation: the RESCUE-AF trial. Circ Arrhythm Electrophysiol. 2019;12:e007044.
Ho SY, Cabrera JA, Sanchez-Quintana D. Left atrial anatomy revisited. Circ Arrhythm Electrophysiol. 2012;5:220-228.
O'Keefe EL, Sturgess JE, O'Keefe JH, Gupta S, Lavie CJ. Prevention and treatment of atrial fibrillation via risk factor modification. Am J Cardiol. 2021;160:46-52.
Zhou M, Wang H, Chen J, Zhao L. Epicardial adipose tissue and atrial fibrillation: possible mechanisms, potential therapies, and future directions. Pacing Clin Electrophysiol. 2020;43:133-145.
Tao S, Guttman MA, Fink S, et al. Ablation lesion characterization in scarred substrate assessed using cardiac magnetic resonance. JACC Clin Electrophysiol. 2019;5:91-100.
Barkagan M, Leshem E, Shapira-Daniels A, et al. Histopathological characterization of radiofrequency ablation in ventricular scar tissue. JACC Clin Electrophysiol. 2019;5:920-931.
Garg L, Pothineni NVK, Daw JM, et al. Impact of left atrial bipolar electrogram voltage on first pass pulmonary vein isolation during radiofrequency catheter ablation. Front Physiol. 2020;11:594654.
Rodríguez-Mañero M, Valderrábano M, Baluja A, et al. Validating left atrial low voltage areas during atrial fibrillation and atrial flutter using multielectrode automated electroanatomic mapping. JACC Clin Electrophysiol. 2018;4:1541-1552.
Sairaku A, Yoshida Y, Nakano Y, et al. Who is the operator, that is the question: a multicentre study of catheter ablation of atrial fibrillation. Europace. 2016;18:1352-1356.
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305-315.
Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace. 2021;23:1033-1041.
Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384:316-324.
Leung LWM, Akhtar Z, Seshasai SRK, Gallagher MM. First-line management of paroxysmal atrial fibrillation: is it time for a ‘pill in the bin’ approach? A discussion on the STOP AF First, EARLY AF, Cryo-FIRST, and EAST-AF NET 4 clinical trials. EP Europace. 2022;24:533-537.
Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. Circ Arrhythm Electrophysiol. 2020;13:e008128.
Joglar JA, Chung MK, Armbruster AL, et al. ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation Nov. 2023;30:2023.

Auteurs

Omar Kreidieh (O)

Tulane University School of Medicine, New Orleans, Louisiana, USA.

Tina D Hunter (TD)

CTI Clinical Trial and Consulting, Covington, Kentucky, USA.

Sandeep Goyal (S)

Piedmont Atlanta Hospital, Atlanta, Georgia, USA.

Allyson L Varley (AL)

Heart Rhythm Clinical Research Solutions, Birmingham, Alabama, USA.

Christopher Thorne (C)

Heart Rhythm Clinical Research Solutions, Birmingham, Alabama, USA.

Jose Osorio (J)

Heart Rhythm Clinical Research Solutions, Birmingham, Alabama, USA.
Arrhythmia Institute at Grandview, Birmingham, Alabama, USA.

Josh Silverstein (J)

Allegheny Health Network, Pittsburgh, Pennsylvania, USA.

Paul Varosy (P)

Medicine-Cardiology, University of Colorado, Denver, Aurora, Colorado, USA.

Mark Metzl (M)

NorthShore University Health System, Bannockburn, Illinois, USA.

Jordan Leyton-Mange (J)

MaineHealth, Scarborough, Maine, USA.

David Singh (D)

John A Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.

Anil Rajendra (A)

Arrhythmia Institute at Grandview, Birmingham, Alabama, USA.

Antonio Moretta (A)

Heart Rhythm Consultants, Siesta Key, Florida, USA.

Paul C Zei (PC)

Brigham and Women's Hospital, Boston, Massachusetts, USA.

Classifications MeSH